Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Guidance

Subcategories:Clinical Criteria/GuidelinesEthicsLegal UpdatesLegislation & AdvocacyMeeting ReportsResearch Rheum

Figure 2: High-resolution computed tomography showed evidence of interstitial lung disease.

High-resolution computed tomography shows evidence of ILD.

The ACR/CHEST ILD Guidelines in Practice, a video
In collaboration with the American College of Chest Physicians, the ACR released two new comprehensive guidelines aimed at improving the screening, monitoring, and treatment of patients with interstitial lung disease (ILD) secondary to systemic autoimmune rheumatic diseases (SARDs). Recently, Sindhu R. Johnson, MD, PhD, professor of medicine at the University of Toronto, Canada, director of the Toronto Scleroderma Program and principal investigator for the guideline, and Elana J. Bernstein, MD, MSc, Florence Irving associate professor of medicine in the Division of Rheumatology at Columbia University, New York City, and co-first author, presented a webinar to talk about how the guidelines were developed and present some of the recommendations and their rationale: Watch the recording now!

 

On Twitter, @ACRheumDC Puts Advocacy Updates at Your Fingertips

From the College  |  May 8, 2021

The new Twitter account enables quick communication between ACR advocacy staff and ACR/ARP members about the policies, regulations and legislation that affect rheumatology patients and providers and how members can get involved.

RheumPAC Donors Discuss Healthcare Legislation, Drug Pricing with Rep. Lloyd Doggett

Zach Wallace, MD, MSc  |  May 7, 2021

At a virtual event with the chair of the Ways & Means Subcommittee on Health, RheumPAC donors were able to share concerns and recommendations about drug pricing policies and how they affect providers and patients.

ACR Advocates Against VIVIO Interference in Patient Care Decisions

From the College  |  May 7, 2021

The ACR is advocating against policies that threaten patient access and disrupt practice workflow, including non-medical switching, tapering patients off biologics, specialty pharmacy acquisition mandates and site-of-service restrictions.

Spring Review of 2021 State Legislative Progress

Joseph Cantrell, JD  |  May 7, 2021

Bright spots from this legislative session include utilization management reform, copay accumulator bans and pharmacy benefit manager reform.

RA Shortens Life Expectancy of Patients with RA & Increases Healthcare Costs

Arthritis & Rheumatology  |  April 27, 2021

RA shortens life expectancy, even with advances in treatment—and more so for women than for men, according to new research by Chiu et al.

The 21st Century Cures Act Information-Blocking Rule

Steven M. Harris, Esq.  |  April 17, 2021

The 21st Century Cures Act (Cures Act) became law on Dec. 13, 2016, and emphasized interoperability in the exchange of healthcare information between healthcare providers, health information entities and patients. The Cures Act underscored unimpeded access to patient electronic health information (EHI) upon request, in a manner that is secure and updated automatically, and prohibits…

Marc R. Chevrier, MD, PhD, FACR, Lupus Research Memorial Fund Established

From the College  |  April 17, 2021

The Lupus and Allied Diseases Association Inc. established the Marc R. Chevrier, MD, PhD, FACR, Lupus Research Memorial Fund at the Rheumatology Research Foundation, effective March 1. This fund was established to honor the life and legacy of Marc Chevrier, MD, PhD, FACR, a pioneer and patient advocate in the field of lupus. About Dr….

What the ARP & the College Are Doing For You

Christine Stamatos, DNP, ANP-C  |  April 17, 2021

As we emerge from the grips of a global pandemic, we are taking this opportunity to pause and reflect on the ARP and what our division brings to the care of our patients. I found the words of Amanda Gordon’s inaugural reading of her poem, “The Hill We Climb,” inspirational and instructive for our past,…

Stock Footage Inc / shutterstock.com

ACR, Ophthalmologists & Dermatologists Issue Joint Hydroxychloroquine Statement

Ruth Jessen Hickman, MD  |  April 17, 2021

Since 1991, hydroxychloroquine (HCQ) has been a staple for the treatment of patients with systemic lupus erythematosus; it has been shown to improve survival, reduce cardiovascular risk, thrombosis and renal damage, delay or prevent lupus cerebritis and more. However, HCQ can potentially bind in the retinal pigment epithelium and cause degeneration of photoreceptors, leading to…

HHS Secretary Xavier Becerra Extends Public Health Emergency

Amanda Grimm Wiegrefe, MScHSRA  |  April 16, 2021

The COVID-19 public health emergency (PHE) has been extended, effective April 21. The Biden administration has indicated it will likely extend the PHE through the end of the year.

  • « Previous Page
  • 1
  • …
  • 65
  • 66
  • 67
  • 68
  • 69
  • …
  • 309
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences